Hope for next-gen COVID-19 vaccines may rest in an unexpected region of the virus
Researchers further elucidated how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. The study, published in Science on May 4, describes how antibodies targeting sections of the virus outside of the receptor-binding domain may be useful in the development of vaccines and therapies. Read More
Vaxart's oral COVID-19 vaccine shows broad effectiveness in early trials
Vaxart said that new phase I clinical trial data demonstrate that its VXA-CoV2-1 oral COVID-19 tablet vaccine yields broad cross-coronavirus activity. Read More
NanoString tech used to develop SARS-CoV-2 lung cell atlas
NanoString Technologies' GeoMX digital spatial profiler (DSP) technology has been used to develop a foundational dataset to better understand the biological effect of SARS-CoV-2 infection in human lungs and support the identification of new therapeutic interventions and prevention strategies. Read More
Ocugen touts COVID-19 vaccine preclinical results
Ocugen is highlighting clinical study results that show that the Covaxin COVID-19 vaccine from Bharat Biotech of India is effective against the SARS-CoV-2 Brazil variant, B.1.128.2. Read More
Moderna secures WHO emergency use listing for COVID-19 vaccine
Moderna has secured emergency use listing from the World Health Organization (WHO) for its COVID-19 vaccine. Read More
Novavax expands COVID-19 vaccine trial to include adolescents
Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19. Read More
Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine Comirnaty in adolescents 12 to 15 years of age to the European Medicines Agency (EMA) . Read More
How the South African SARS-CoV-2 variant evades antibodies
Computer modeling has demonstrated that one of the three mutations of the South African SARS-CoV-2 variant reduces its ability to bind to human cells. The results, published recently in the Journal of Medicinal Chemistry, also suggest that the mutation may help it escape some therapeutic antibodies. Read More
Brii COVID-19 mAb combo advances to phase III NIH trial
Brii Biosciences announced that it is enrolling patients in a phase III trial of its monoclonal antibody (mAb) combination therapy, BRII-196 and BRII-198, after meeting phase II safety and efficacy criteria. Read More
Bavarian Nordic posts positive preclinical data for its COVID-19 vaccine
Bavarian Nordic reported that additional preclinical data confirms its COVID-19 vaccine candidate can induce neutralizing antibodies against SARS-CoV-2 variants. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter